Mesoblast Financial Results and Corporate Update Webcast
Rhea-AI Summary
Mesoblast (Nasdaq:MESO) will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The live webcast begins at 5:00 PM EST on Thursday, February 26, 2026 (9:00 AM AEDT, Friday, February 27, 2026).
According to the company, the webcast is accessible at the provided OpenBriefing link and an archived replay will be posted on Mesoblast's Investor page.
Positive
- None.
Negative
- None.
News Market Reaction – MESO
On the day this news was published, MESO declined 0.27%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows ARDX moving down 7.57% with no news. Other biotech peers show mixed moves (some up, some down), suggesting this earnings webcast notice is stock-specific rather than part of a coordinated sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Aug 27 | Earnings webcast notice | Neutral | +0.8% | Scheduled webcast to discuss full-year 2025 financial results and operations. |
| Feb 25 | Earnings webcast notice | Neutral | -2.1% | Announced webcast for half-year 2024 financial and operational discussion. |
| Aug 28 | Full-year results update | Neutral | +1.6% | Reported FY2024 financial results and key regulatory and clinical milestones. |
| Aug 27 | Earnings webcast notice | Neutral | +0.2% | Scheduled webcast for FY2024 financial and operational highlights. |
| Feb 28 | Half-year results update | Neutral | -5.7% | Reported financial results and operations for half-year ended Dec 31, 2023. |
Past earnings-related announcements have led to both positive and negative single-day price reactions.
Recent earnings-tagged events for Mesoblast show a pattern where webcast announcements around results, and full financial updates, have been followed by modest single-day moves in both directions. Events on Feb 28, 2024 and Aug 28, 2024 involved detailed financial and operational updates, while several other items, like the Aug 27, 2025 and Feb 25, 2025 notices, simply scheduled webcasts. Today’s half-year webcast announcement fits this established pattern of using calls to frame financial results and operational progress.
Historical Comparison
Over the past five earnings-tagged events, MESO’s average move was -1.06%, with both webcast notices and full financial updates producing modest, mixed reactions.
Earnings communications have progressed from reporting large losses and cash usage to pairing results with regulatory milestones and commercial updates, using webcasts to frame these developments.
Market Pulse Summary
This announcement schedules a webcast to discuss Mesoblast’s half-year results to December 31, 2025, continuing its practice of pairing earnings with corporate updates. Prior earnings-tagged events have produced modest, mixed price moves, with an average reaction of -1.06%. Investors may focus on revenue trends, cash balance and operating spend alongside ongoing commercialization and trial activity. Key items to watch include any changes to cash runway, borrowing plans, and how management frames regulatory and commercial milestones.
Key Terms
allogeneic cellular medicines medical
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025.
The webcast will begin at 5.00pm EST, Thursday, February 26; 9.00am AEDT, Friday, February 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-hyr-2026/
The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Rubenstein | BlueDot Media |
| Caroline Nelson | Steve Dabkowski |
| T: +1 703 489 3037 | T: +61 419 880 486 |
| E: cnelson@rubenstein.com | E: steve@bluedot.net.au |
FAQ
When is Mesoblast's (MESO) webcast on half year results for Dec 31, 2025?
How can investors access the Mesoblast (MESO) live webcast on February 26, 2026?
Will Mesoblast (MESO) provide a replay of the February 26, 2026 webcast?
What topics will Mesoblast (MESO) cover in the February 26, 2026 webcast?
What time should international investors dial in for Mesoblast's (MESO) February 26 webcast?
